Alnylam Pharmaceuticals Files Patent Infringement Suits against Pfizer and Moderna
CAMBRIDGE, MA (ClassActionDaily) Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) the leading RNAi therapeutics company, announced today that it has separately filed suit in United States District Court for the District of Delaware against Pfizer, Inc. and Moderna, Inc., seeking damages for infringement of U.S. Patent No. 11,246,933 (the “’933 Patent”) in the parties’ manufacture and sale of their messenger RNA (mRNA) COVID-19 vaccines. The patent relates to Alnylam’s biodegradable cationic lipids that are foundational to the success of the mRNA COVID-19 vaccines. The complaints can be accessed on Alnylam’s website (Pfizer and Moderna).
Alnylam is seeking fair compensation for use of its technology based on patent claims to a broad class of biodegradable lipids invented over a decade ago resulting from extensive research and investment. The Company is proud that this work has supported rapid development of the life-saving vaccines. Alnylam does not intend to seek an injunction or take action that impedes production, sale or distribution of the vaccines.